The Pathogenic Mechanism of the Virulence Factor, Mycolactone, Depends on Blockade of Protein Translocation into the ER

English version České info

Buruli ulcer is a progressive necrotic skin lesion caused by infection with the human pathogen Mycobacterium ulcerans. Mycolactone, a small compound produced by the mycobacterium, is the root cause of the disease pathology, but until now there has been no unifying mechanism explaining why. We have been using a model system to investigate the reason for the selective loss of protein that is a common feature of mycolactone exposure. Specifically, this involves identifying the point at which it stops immune cells making inflammatory mediators. In this work, we demonstrate that mycolactone inhibits production of such proteins by blocking the first step of protein export: translocation into a cellular compartment called the endoplasmic reticulum (ER). Proteins due for export are instead made in the cell cytosol where they are recognised as being in the wrong place and are rapidly degraded, causing a general cessation of the production of proteins that have to travel through the ER, including almost all secreted and surface proteins. This has a profound effect on basic cell functions such as growth, adhesion and survival. Therefore, we have identified the molecular basis underlying the key features of Buruli ulcer, and this will transform our understanding of disease progression.

Vyšlo v časopise: The Pathogenic Mechanism of the Virulence Factor, Mycolactone, Depends on Blockade of Protein Translocation into the ER. PLoS Pathog 10(4): e32767. doi:10.1371/journal.ppat.1004061
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004061

Souhrn

Zdroje

1. GeorgeKM, ChatterjeeD, GunawardanaG, WeltyD, HaymanJ, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283 : 854–857.

2. DemangelC, StinearTP, ColeST (2009) Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol 7 : 50–60.

3. StinearTP, Mve-ObiangA, SmallPL, FriguiW, PryorMJ, et al. (2004) Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A 101 : 1345–1349.

4. HallBS, SimmondsRE (2013) Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer. Biochem Soc Trans 42 : 177–183.

5. SimmondsRE, LaliFV, SmallieT, SmallPL, FoxwellBM (2009) Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol 182 : 2194–2202.

6. Guenin-MaceL, CarretteF, Asperti-BoursinF, Le BonA, CaleechurnL, et al. (2011) Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression. Proc Natl Acad Sci U S A 108 : 12833–12838.

7. GeorgeKM, PascopellaL, WeltyDM, SmallPL (2000) A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 68 : 877–883.

8. Guenin-MaceL, Veyron-ChurletR, ThoulouzeMI, Romet-LemonneG, HongH, et al. (2013) Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest 123 : 1501–1512.

9. OliveiraMS, FragaAG, TorradoE, CastroAG, PereiraJP, et al. (2005) Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun 73 : 6299–6310.

10. TorradoE, AdusumilliS, FragaAG, SmallPL, CastroAG, et al. (2007) Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 75 : 3979–3988.

11. HongH, CoutanceauE, LeclercM, CaleechurnL, LeadlayPF, et al. (2008) Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2: e325.

12. AdusumilliS, Mve-ObiangA, SparerT, MeyersW, HaymanJ, et al. (2005) Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 7 : 1295–1304.

13. CoutanceauE, MarsollierL, BroschR, PerretE, GoossensP, et al. (2005) Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 7 : 1187–1196.

14. FragaAG, CruzA, MartinsTG, TorradoE, SaraivaM, et al. (2011) Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun 79 : 421–430.

15. PahlevanAA, WrightDJ, AndrewsC, GeorgeKM, SmallPL, et al. (1999) The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol 163 : 3928–3935.

16. CoutanceauE, DecalfJ, MartinoA, BabonA, WinterN, et al. (2007) Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 204 : 1395–1403.

17. BoulkrounS, Guenin-MaceL, ThoulouzeMI, MonotM, MerckxA, et al. (2010) Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol 184 : 1436–1444.

18. PhillipsR, SarfoFS, Guenin-MaceL, DecalfJ, Wansbrough-JonesM, et al. (2009) Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. J Infect Dis 200 : 1675–1684.

19. MartinsTG, TrigoG, FragaAG, GamaJB, Longatto-FilhoA, et al. (2012) Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection. PLoS Negl Trop Dis 6: e1925.

20. SchutteD, Um-BoockA, Mensah-QuainooE, ItinP, SchmidP, et al. (2007) Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 1: e2.

21. AndersonP (2008) Post-transcriptional control of cytokine production. Nat Immunol 9 : 353–359.

22. AzzamME, AlgranatiID (1973) Mechanism of puromycin action: fate of ribosomes after release of nascent protein chains from polysomes. Proc Natl Acad Sci U S A 70 : 3866–3869.

23. IngoliaNT, LareauLF, WeissmanJS (2011) Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes. Cell 147 : 789–802.

24. RapoportTA (2007) Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. Nature 450 : 663–669.

25. LernerRS, SeiserRM, ZhengT, LagerPJ, ReedyMC, et al. (2003) Partitioning and translation of mRNAs encoding soluble proteins on membrane-bound ribosomes. RNA 9 : 1123–1137.

26. StephensSB, DoddRD, LernerRS, PyhtilaBM, NicchittaCV (2008) Analysis of mRNA partitioning between the cytosol and endoplasmic reticulum compartments of mammalian cells. Methods Mol Biol 419 : 197–214.

27. SimmondsRE, FoxwellBM (2008) Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 47 : 584–590.

28. OlszewskiMB, TrzaskaD, KnolEF, AdamczewskaV, DastychJ (2006) Efficient sorting of TNF-alpha to rodent mast cell granules is dependent on N-linked glycosylation. Eur J Immunol 36 : 997–1008.

29. BesemerJ, HarantH, WangS, OberhauserB, MarquardtK, et al. (2005) Selective inhibition of cotranslational translocation of vascular cell adhesion molecule 1. Nature 436 : 290–293.

30. GarrisonJL, KunkelEJ, HegdeRS, TauntonJ (2005) A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum. Nature 436 : 285–289.

31. CrossBC, McKibbinC, CallanAC, RobotiP, PiacentiM, et al. (2009) Eeyarestatin I inhibits Sec61-mediated protein translocation at the endoplasmic reticulum. J Cell Sci 122 : 4393–4400.

32. SnyderDS, SmallPL (2003) Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb Pathog 34 : 91–101.

33. RabuC, SchmidV, SchwappachB, HighS (2009) Biogenesis of tail-anchored proteins: the beginning for the end? J Cell Sci 122 : 3605–3612.

34. RajanRS, TsumotoK, TokunagaM, TokunagaH, KitaY, et al. (2011) Chemical and pharmacological chaperones: application for recombinant protein production and protein folding diseases. Curr Med Chem 18 : 1–15.

35. TokunagaF, BrostromC, KoideT, ArvanP (2000) Endoplasmic reticulum (ER)-associated degradation of misfolded N-linked glycoproteins is suppressed upon inhibition of ER mannosidase I. J Biol Chem 275 : 40757–40764.

36. MbonyeUR, WadaM, RiekeCJ, TangHY, DewittDL, et al. (2006) The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J Biol Chem 281 : 35770–35778.

37. PatelNR, BoleM, ChenC, HardinCC, KhoAT, et al. (2012) Cell elasticity determines macrophage function. PLoS One 7: e41024.

38. Van den BergB, ClemonsWMJr, CollinsonI, ModisY, HartmannE, et al. (2004) X-ray structure of a protein-conducting channel. Nature 427 : 36–44.

39. HegdeRS, KeenanRJ (2011) Tail-anchored membrane protein insertion into the endoplasmic reticulum. Nat Rev Mol Cell Biol 12 : 787–798.

40. van de VeerdonkFL, NeteaMG, DinarelloCA, JoostenLA (2011) Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol 32 : 110–116.

41. PelegrinP, Barroso-GutierrezC, SurprenantA (2008) P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J Immunol 180 : 7147–7157.

42. LiuY, LawBK, LueschH (2009) Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation. Mol Pharmacol 76 : 91–104.

43. WangQ, ShinkreBA, LeeJG, WenigerMA, LiuY, et al. (2010) The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group. PLoS One 5: e15479.

44. McKibbinC, MaresA, PiacentiM, WilliamsH, RobotiP, et al. (2012) Inhibition of protein translocation at the endoplasmic reticulum promotes activation of the unfolded protein response. Biochem J 442 : 639–648.

45. LunaA, MatasOB, Martinez-MenarguezJA, MatoE, DuranJM, et al. (2002) Regulation of protein transport from the Golgi complex to the endoplasmic reticulum by CDC42 and N-WASP. Mol Biol Cell 13 : 866–879.

46. ThrasherAJ, BurnsSO (2010) WASP: a key immunological multitasker. Nat Rev Immunol 10 : 182–192.

47. GoodingTM, JohnsonPD, CampbellDE, HaymanJA, HartlandEL, et al. (2001) Immune response to infection with Mycobacterium ulcerans. Infect Immun 69 : 1704–1707.

48. GoodingTM, KempAS, Robins-BrowneRM, SmithM, JohnsonPD (2003) Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin Infect Dis 36 : 1076–1077.

49. NienhuisWA, StienstraY, AbassKM, TuahW, ThompsonWA, et al. (2012) Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 54 : 519–526.

50. MartinsTG, GamaJB, FragaAG, SaraivaM, SilvaMT, et al. (2012) Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection. PLoS One 7: e32740.

51. SarfoFS, ConversePJ, AlmeidaDV, ZhangJ, RobinsonC, et al. (2013) Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis 7: e2101.

52. AlmeidaDV, ConversePJ, LiSY, TyagiS, NuermbergerEL, et al. (2013) Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis 7: e2085.

53. YuhasY, BerentE, AshkenaziS (2011) Effect of rifampin on production of inflammatory mediators in HepG2 liver epithelial cells. Antimicrob Agents Chemother 55 : 5541–5546.

54. PahlevanAA, WrightDJ, BradleyL, SmithC, FoxwellBM (2002) Potential of rifamides to inhibit TNF-induced NF-kappaB activation. J Antimicrob Chemother 49 : 531–534.

55. SongF, FidanzeS, BenowitzAB, KishiY (2002) Total synthesis of the mycolactones. Org Lett 4 : 647–650.

56. JohannesG, SarnowP (1998) Cap-independent polysomal association of natural mRNAs encoding c-myc, BiP, and eIF4G conferred by internal ribosome entry sites. RNA 4 : 1500–1513.

57. PowleyIR, KondrashovA, YoungLA, DobbynHC, HillK, et al. (2009) Translational reprogramming following UVB irradiation is mediated by DNA-PKcs and allows selective recruitment to the polysomes of mRNAs encoding DNA repair enzymes. Genes Dev 23 : 1207–1220.

58. WalterP, BlobelG (1983) Preparation of microsomal membranes for cotranslational protein translocation. Methods Enzymol 96 : 84–93.

59. WilsonR, AllenAJ, OliverJ, BrookmanJL, HighS, et al. (1995) The translocation, folding, assembly and redox-dependent degradation of secretory and membrane proteins in semi–permeabilized mammalian cells. Biochem J 307(Pt 3): 679–687.

60. ShekarPC, GoelS, RaniSD, SarathiDP, AlexJL, et al. (2006) kappa-casein-deficient mice fail to lactate. Proc Natl Acad Sci U S A 103 : 8000–8005.